These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 22462553

  • 1. STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
    Huang DY, Chao Y, Tai MH, Yu YH, Lin WW.
    J Biomed Sci; 2012 Mar 30; 19(1):35. PubMed ID: 22462553
    [Abstract] [Full Text] [Related]

  • 2. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S.
    Cancer Res; 2002 Jan 01; 62(1):188-99. PubMed ID: 11782377
    [Abstract] [Full Text] [Related]

  • 3. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
    Liu JH, Liu CC, Yen CC, Gau JP, Wang WS, Tzeng CH.
    Int J Cancer; 2009 Jul 01; 125(1):71-7. PubMed ID: 19291793
    [Abstract] [Full Text] [Related]

  • 4. Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C.
    Sánchez-Arévalo Lobo VJ, Aceves Luquero CI, Alvarez-Vallina L, Tipping AJ, Viniegra JG, Hernández Losa J, Parada Cobo C, Galán Moya EM, Gayoso Cruz J, Melo JV, Ramón y Cajal S, Sánchez-Prieto R.
    Biochem J; 2005 Apr 01; 387(Pt 1):231-8. PubMed ID: 15540985
    [Abstract] [Full Text] [Related]

  • 5. STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits.
    Cancino GI, Toledo EM, Leal NR, Hernandez DE, Yévenes LF, Inestrosa NC, Alvarez AR.
    Brain; 2008 Sep 01; 131(Pt 9):2425-42. PubMed ID: 18559370
    [Abstract] [Full Text] [Related]

  • 6. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
    Lee YL, Chen CW, Liu FH, Huang YW, Huang HM.
    PLoS One; 2013 Sep 01; 8(4):e61939. PubMed ID: 23613979
    [Abstract] [Full Text] [Related]

  • 7. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.
    Nica AF, Tsao CC, Watt JC, Jiffar T, Kurinna S, Jurasz P, Konopleva M, Andreeff M, Radomski MW, Ruvolo PP.
    Cell Cycle; 2008 Nov 01; 7(21):3362-70. PubMed ID: 18948750
    [Abstract] [Full Text] [Related]

  • 8. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
    Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, Tefferi A, Kaufmann SH.
    Blood; 2002 Jan 15; 99(2):664-71. PubMed ID: 11781252
    [Abstract] [Full Text] [Related]

  • 9. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
    Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, Majchrzak B, Ravandi F, Tallman MS, Fish EN, Platanias LC.
    J Biol Chem; 2004 Jun 11; 279(24):25345-52. PubMed ID: 15056660
    [Abstract] [Full Text] [Related]

  • 10. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S.
    Blood; 2003 Nov 15; 102(10):3765-74. PubMed ID: 12893773
    [Abstract] [Full Text] [Related]

  • 11. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
    Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M.
    Blood; 2003 Jan 15; 101(2):690-8. PubMed ID: 12509383
    [Abstract] [Full Text] [Related]

  • 12. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
    Rahmani M, Reese E, Dai Y, Bauer C, Kramer LB, Huang M, Jove R, Dent P, Grant S.
    Mol Pharmacol; 2005 Apr 15; 67(4):1166-76. PubMed ID: 15625278
    [Abstract] [Full Text] [Related]

  • 13. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
    Dai Y, Rahmani M, Pei XY, Dent P, Grant S.
    Blood; 2004 Jul 15; 104(2):509-18. PubMed ID: 15039284
    [Abstract] [Full Text] [Related]

  • 14. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
    Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A, Takahashi K, Kagami K, Yamaguchi N, Yagita H, Okumura K, Koyama-Okazaki T, Suzuki T, Sugita K, Nakazawa S.
    Blood; 2003 May 01; 101(9):3658-67. PubMed ID: 12506034
    [Abstract] [Full Text] [Related]

  • 15. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S.
    Cancer Res; 2003 May 01; 63(9):2118-26. PubMed ID: 12727828
    [Abstract] [Full Text] [Related]

  • 16. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
    Kawauchi K, Ogasawara T, Yasuyama M, Ohkawa Si.
    Blood Cells Mol Dis; 2003 May 01; 31(1):11-7. PubMed ID: 12850478
    [Abstract] [Full Text] [Related]

  • 17. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C, Bhalla K.
    Clin Cancer Res; 2001 Feb 01; 7(2):350-7. PubMed ID: 11234890
    [Abstract] [Full Text] [Related]

  • 18. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
    Sun X, Layton JE, Elefanty A, Lieschke GJ.
    Blood; 2001 Apr 01; 97(7):2008-15. PubMed ID: 11264165
    [Abstract] [Full Text] [Related]

  • 19. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.
    Mutat Res; 2006 Jan 31; 603(1):74-82. PubMed ID: 16388976
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J, Myloch S, Nürnberger H, Rossmanith T, Hofmann WK, Hoelzer D, Ottmann OG.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.